Dr. Lianna J. Marks, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
725 Welch Rd
Palo Alto, CA 94304
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2011
Licensed in California since 2018, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
CA license A156744 (first issued 2018; current) · NY license 274578 -
Pediatrics Physician
CA license A156744 (first issued 2018; current) · PA license MT199234
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 6 payments worth $4,773 in total to this clinician.
| Pierre Fabre Pharmaceuticals, Inc. | $4,773 |
|---|
| Honoraria | $3,750 |
|---|---|
| Travel and Lodging | $908 |
| Food and Beverage | $116 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pierre Fabre Pharmaceuticals, Inc. May 30, 2025 | Honoraria | $3,750 |
| Pierre Fabre Pharmaceuticals, Inc. May 30, 2025 | Travel and Lodging travel to ROSEMONT, IL | $584 |
| Pierre Fabre Pharmaceuticals, Inc. May 30, 2025 | Travel and Lodging travel to ROSEMONT, IL | $226 |
| Pierre Fabre Pharmaceuticals, Inc. May 30, 2025 | Travel and Lodging travel to ROSEMONT, IL | $98.43 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $47,558 in research payments for these studies, mostly to the institutions running them.
- Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
AbbVie Inc. · Active, not recruiting · NCT05206357 - A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
E.r. Squibb & Sons, L.l.c. · Terminated · NCT05255601 - Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) I…
AbbVie Inc. - M20-429 - Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutane…
AbbVie Inc. - A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical Hodgkin Lymphoma a…
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.